PharmAthene
Annapolis
About PharmAthene
PharmAthene, Inc., a biodefense company, develops medical countermeasures to prevent and treat morbidity and mortality associated with the use of biological and chemical weapons in the United States. Its products, which are under development, include Valortim, a prophylactic and therapeutic anti-anthrax monoclonal antibody; and Protexia, a recombinant form of human butyrylcholinesterase for clinical use in the treatment of organophosphate intoxication due to exposure to chemical nerve agents. The company was founded in 2001 and is headquartered in Annapolis, Maryland.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $100K – $500K
- Total funding: $84.3M
- Funding stage: M&A
- Last round: Post-IPO Secondary (Jul 2009)
- Ticker: nysemkt:PIP
- Website: pharmathene.com
- Phone: +1 4102 692 601
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/pharmathene-1924343 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.